By studying the levels of five serum liver fibrosis markers in OSA patients, a novel marker—CHI3L1—was found, and detecting CHI3L1 content in serum is safer and faster than detecting other markers. This evidence concerns the gene CHI3L1 and Hepatic fibrosis.